- Shares of PTC Therapeutics ( PTCT ) are up ~6% in Monday afternoon trading ahead of the company Q2 2022 earnings call after the closing bell on August 4.
- The company also hit a 52-week highof $47.57.
- The Q2 revenue consensus estimate is $162.53M, while the normalized EPS estimate is -$1.48
- PTC Therapeutics' ( PTCT ) gene replacement therapy Upstaza (eladocagene exuparvovec) was recently approved by the European Commission to treat aromatic L-amino acid decarboxylase (AADC) deficiency.
For further details see:
PTC Therapeutics up 6% in advance of August 4 quarterly earnings; hits 52-week high